During the past decade, Institut Catala d Oncologia Hospital Duran i Reynals conducted 287 clinical trials. In the 10-year time frame, 287 clinical trials started and 79 clinical trials were completed, i.e. on average, 27.5% percent of trials that started reached the finish line to date. In the past 5 years, 97 clinical trials started and 51 clinical trials were completed. i.e. 52.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Catala d Oncologia Hospital Duran i Reynals" #1 sponsor was "Hoffmann-La Roche" with 47 trials, followed by "PETHEMA Foundation" with 17 trials sponsored, "Pfizer" with 16 trials sponsored, "Celgene" with 14 trials sponsored and "Janssen Research & Development, LLC" with 14 trials sponsored. Other sponsors include 280 different institutions and companies that sponsored additional 123 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Catala d Oncologia Hospital Duran i Reynals" #1 collaborator was "AstraZeneca" with 12 trials as a collaborator, "Pfizer" with 12 trials as a collaborator, "Apices Soluciones S.L." with 11 trials as a collaborator, "Hoffmann-La Roche" with 8 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 7 trials as a collaborator. Other collaborators include 202 different institutions and companies that were collaborators in the rest 160 trials.

According to Clinical.Site data, the most researched conditions in "Institut Catala d Oncologia Hospital Duran i Reynals" are "Breast Cancer" (27 trials), "Carcinoma, Non-Small-Cell Lung" (16 trials), "Multiple Myeloma" (16 trials), "Myelodysplastic Syndromes" (10 trials) and "Lung Cancer" (9 trials). Many other conditions were trialed in "Institut Catala d Oncologia Hospital Duran i Reynals" in a lesser frequency.

Most popular intervention types in "Institut Catala d Oncologia Hospital Duran i Reynals" are "Drug" (350 trials), "Other" (31 trials), "Radiation" (20 trials), "Biological" (18 trials) and "Procedure" (11 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (47 trials), "Carboplatin" (28 trials), "Paclitaxel" (28 trials), "Atezolizumab" (23 trials) and "Cisplatin" (19 trials). Other intervention names were less common.

The vast majority of trials in "Institut Catala d Oncologia Hospital Duran i Reynals" are 343 trials for "All" genders, 32 trials for "Female" genders and 16 trials for "Male" genders.

Currently, there are 189 active trials in "Institut Catala d Oncologia Hospital Duran i Reynals". 3 are not yet recruiting, 84 are recruiting, 101 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 155 completed trials in Institut Catala d Oncologia Hospital Duran i Reynals, undefined suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Catala d Oncologia Hospital Duran i Reynals, 67 "Phase 1" clinical trials were conducted, 172 "Phase 2" clinical trials and 146 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 6 trials that are defined as “Not Applicable".

Institut Catala d Oncologia Hospital Duran i Reynals has several departments that took part in Clinical trials: "Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia" - 10 trials, "Institut Catala d'Oncologia" - 77 trials, "Ico Institut Catala D Oncologia" - 4 trials, "Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia" - 2 trials, "ICO Girona - Hospital Doctor Josep Trueta (Institut Catala D'Oncologia)" - 2 trials